Resverlogix Corp. (RVX) - Total Liabilities
Based on the latest financial reports, Resverlogix Corp. (RVX) has total liabilities worth CA$102.36 Million CAD (≈ $74.05 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Resverlogix Corp. to evaluate the company's liquid asset resilience ratio.
Resverlogix Corp. - Total Liabilities Trend (2001–2025)
This chart illustrates how Resverlogix Corp.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Resverlogix Corp. balance sheet assets.
Resverlogix Corp. Competitors by Total Liabilities
The table below lists competitors of Resverlogix Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nord Insuretech Group AB
ST:NORDIG
|
Sweden | Skr28.10 Million |
|
Ulima Nitra PT
JK:UNIQ
|
Indonesia | Rp272.93 Billion |
|
Alpcot Holding AB Series B
ST:ALPCOT-B
|
Sweden | Skr98.89 Million |
|
Pantera Silver Corp
V:PNTR
|
Canada | CA$150.53K |
|
KPX Lifescience.Co.Ltd
KQ:114450
|
Korea | ₩15.22 Billion |
|
Panca Global Securities Tbk
JK:PEGE
|
Indonesia | Rp46.19 Billion |
|
Hamashbir 365 Holdings Ltd
TA:MSBI
|
Israel | ILA1.33 Billion |
|
Fuji Finance Indonesia Tbk PT
JK:FUJI
|
Indonesia | Rp8.65 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Resverlogix Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See RVX net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 12.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Resverlogix Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Resverlogix Corp. (2001–2025)
The table below shows the annual total liabilities of Resverlogix Corp. from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$96.73 Million ≈ $69.98 Million |
+8.59% |
| 2024-12-31 | CA$89.08 Million ≈ $64.44 Million |
+9.98% |
| 2023-12-31 | CA$80.99 Million ≈ $58.59 Million |
+20.17% |
| 2022-12-31 | CA$67.40 Million ≈ $48.75 Million |
-3.52% |
| 2021-12-31 | CA$69.85 Million ≈ $50.53 Million |
+38.04% |
| 2020-12-31 | CA$50.60 Million ≈ $36.60 Million |
-32.97% |
| 2019-12-31 | CA$75.49 Million ≈ $54.61 Million |
-66.30% |
| 2018-12-31 | CA$224.01 Million ≈ $162.04 Million |
+143.61% |
| 2017-12-31 | CA$91.95 Million ≈ $66.52 Million |
-18.22% |
| 2016-12-31 | CA$112.44 Million ≈ $81.33 Million |
+16.48% |
| 2015-12-31 | CA$96.53 Million ≈ $69.83 Million |
+1.73% |
| 2014-12-31 | CA$94.88 Million ≈ $68.64 Million |
+43.24% |
| 2013-12-31 | CA$66.24 Million ≈ $47.92 Million |
+32.48% |
| 2012-12-31 | CA$50.00 Million ≈ $36.17 Million |
+419.21% |
| 2011-12-31 | CA$9.63 Million ≈ $6.97 Million |
+133.34% |
| 2010-12-31 | CA$4.13 Million ≈ $2.99 Million |
+3.96% |
| 2009-12-31 | CA$3.97 Million ≈ $2.87 Million |
-45.60% |
| 2008-12-31 | CA$7.30 Million ≈ $5.28 Million |
-52.21% |
| 2007-12-31 | CA$15.27 Million ≈ $11.04 Million |
-4.68% |
| 2006-12-31 | CA$16.02 Million ≈ $11.59 Million |
+2664.70% |
| 2005-12-31 | CA$579.36K ≈ $419.10K |
+63.95% |
| 2004-12-31 | CA$353.37K ≈ $255.62K |
+262.06% |
| 2003-12-31 | CA$97.60K ≈ $70.60K |
-30.21% |
| 2002-12-31 | CA$139.85K ≈ $101.17K |
+292.32% |
| 2001-12-31 | CA$35.65K ≈ $25.79K |
-- |
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID… Read more